Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00579436 · ClinicalTrials.gov registry record · NA

Effects of Fish Oils on Inflammation and Insulin Resistance

A NA study of Insulin Resistance and Metabolic Syndrome, sponsored by Philip Kern.

Completed
Registry status
NA
Development phase
33
Enrollment target
1
Study location

NCT00579436 is a NA study of Insulin Resistance and Metabolic Syndrome that has completed, run by Philip Kern. The registered enrollment target is 33 participants, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00579436, a NA study of Insulin Resistance and Metabolic Syndrome, has completed, sponsored by Philip Kern.

COMPLETED
Registry status
NA
Development phase
33 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine whether improvement in fat and muscle metabolism after the treatment with Omacor (fish oils) provides insight into the link between obesity, fat and muscle function leading to metabolic syndrome, which is a risk factor for heart disease and diabetes.

Interventions

  • DRUG placebo
  • DRUG omega-3 fatty acid

Study Locations (1)

Kentucky

  • University of Kentucky Medical Cener - Lexington

Trial Details

FieldValue
Enrollment Target 33 participants
Start Date 2007-01
Est. Completion 2015-01-15
Phase NA

Sponsor

Philip Kern

9 total trials

What the Registry Record Tells You About NCT00579436

The ClinicalTrials.gov registry entry for NCT00579436 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (87% lower). The listed sponsor is Philip Kern, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Insulin Resistance appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.

NCT00579436 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.

Frequently Asked Questions

What is clinical trial NCT00579436 about?

NCT00579436 is a clinical study titled "Effects of Fish Oils on Inflammation and Insulin Resistance". The purpose of this study is to determine whether improvement in fat and muscle metabolism after the treatment with Omacor (fish oils) provides insight into the link between obesity, fat and muscle function leading to metabolic syndrome, which is a risk factor for heart disease and diabetes.

What is the current status of trial NCT00579436?

This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2007-01. Estimated completion is 2015-01-15.

What conditions does trial NCT00579436 study?

This clinical trial studies the following conditions: Insulin Resistance, Metabolic Syndrome.

What interventions are being tested in trial NCT00579436?

The interventions under investigation include: placebo (DRUG), omega-3 fatty acid (DRUG).

Who is sponsoring clinical trial NCT00579436?

This trial is sponsored by Philip Kern, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00579436 being conducted?

This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Insulin Resistance

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.